ABSTRACT
Background
Drug-induced seizures are a common occurrence in clinical practice, with research indicating that around 6% of initial seizures are due to drug toxicity. The use of antibiotics is one such cause of drug-related seizures. Previous systematic review has identified specific antibiotics that pose a risk of seizures, but a comprehensive analysis of a large patient sample is needed to determine the risk associated with various drugs.
Objective
This study aimed to evaluate the association between seizures and various antibiotics that are presently accessible.
Methods
To identify potential risk signals from the US Food and Drug Administration adverse event reporting system (FAERS) database, a disproportionality analysis was conducted. The reporting odds ratio (ROR) using the frequency approach and the information component (IC) using the Bayesian approach were used to detect signals. The median time-to-onset of seizure, as well as the Weibull distribution parameters were calculated to analyze the onset time.
Results
A total of 14,407,157 FAERS reports were analyzed.10 antibiotics were associated with seizures that were defined by 41 preferred terms. Onset time were aligned with the wear out failure type profile.
Conclusion
This study identified 10 antibiotics that showed significant associations with seizures. Imipenem-cilastatin had the highest seizure ROR.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contribution statement
The study’s concept and design were developed by Zou Dan, while Wu Bin and Zou Dan were responsible for the statistical analysis. All authors contributed to the interpretation of the data. Zou Dan drafted the manuscript, and all authors provided critical revision for important intellectual content.
Acknowledgments
This study was performed using the FDA Adverse Event Reporting System (FAERS) database that was provided by the FDA. The information, results, or interpretation of the current study do not represent any opinion of the FDA. This research was supported by National Key Clinical Specialties Construction Program.